Table 3.

Summary of grade 3, 4, or 5 AEs possibly, probably, or definitely related to alemtuzumab therapy in patients with ATL (N = 29)

Adverse eventGrade 3, n (%)Grade 4, n (%)
Hematologic
 Leukopenia12 (41)5 (17)
 Lymphocytopenia17 (59)0
 Neutropenia9 (31)1 (3)
 Anemia7 (24)0
 Thrombocytopenia3 (10)0
Hepatic
 Alkaline phosphatase1 (3)0
 γ-Glutamyl transpeptidase1 (3)0
 Bilirubin1 (3)0
 Hypoalbuminemia2 (7)0
Metabolic
 Creatinine phosphokinase1 (3)0
 Hypercalcemia1 (3)0
 Hypocalcemia1 (3)0
 Hypokalemia1 (3)0
 Hypophosphatemia1 (3)0
Allergy immunology
 Allergic reaction1 (3)0
Cardiovascular
 Vasovagal episode2 (7)0
 Hypotension3 (10)0
Constitutional symptoms
 Fever in the absence of neutropenia3 (10)0
Pulmonary
 Pulmonary infiltrates1 (3)0
 Pulmonary hypoxia2 (7)0
Ocular/Visual
 Blurred vision1 (3)0
 Photophobia1 (3)0
 (Other) Uveitis1 (3)0
Endocrine
 Hyperthyroidism1 (3)0
Dermatological
 Rash, desquamation1 (3)0
Infection
 With grade 3 or 4 neutropenia2 (7)0
 Without grade 3 or 4 neutropenia2 (7)0